Changjiang Life Science (00775) announced interim results. Losses attributable to shareholders of HK$28.73 million decreased by 80.95% year-on-year

According to the Zhitong Finance App, Changjiang Life Technology (00775) announced its 2026 interim results. The group obtained revenue of HK$2,716 billion, an increase of 4.22% over the previous year; loss attributable to the company's shareholders' equity was HK$28.73 million, a decrease of 80.95%; and a loss of HK0.3 cents per share.

In the second half of 2025, the company will carry out a corporate restructuring to strengthen scientific research development and introduce more expertise and technology to enhance execution capabilities. The restructuring involved the acquisition of Polynoma, a subsidiary of Changjiang Life Science and Technology by US-based NASDAQ listed company TransCode Therapeutics (RNAZ). According to the transaction arrangement, Changjiang Life Science is expected to become the main shareholder of RNAZ. In the first half of 2026, since RNAZ shareholders have not yet approved the change in controlling interest, expenses related to Polynoma and RNAZ were not included in the company's consolidated financial statements. This change in accounting treatment led to a significant reduction in R&D expenses during the review period, resulting in corresponding losses lower than last year.